Brielle Benyon

With the study of more biomarkers for MPNs, the field continues to advance. However, more work still needs to be done.

Recent research, conducted at NYU Langone Health and presented at the Oncology Nursing Society (ONS) Annual Congress, sought to find out how patients with melanoma perceived skin health education, and their willingness be involved in their own surveillance or a loved one’s.

Patients with head and neck cancer experienced a decrease in symptom severity after using mobile and sensor technology that allowed their health care providers to remotely monitor symptoms, according to research that will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

The Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx), a biosimilar of Epogen/Procrit (epoetin alfa), to treat anemia caused by a number of factors – including undergoing chemotherapy.

When compared to chemotherapy, the immunotherapy agent had better outcomes both in quality of life and survival.

Higher carbohydrate and sugar intake was correlated with worse outcomes in patients with head and neck cancer, according to the study.

The treatment landscape of mantle cell lymphoma is continuing to change. See what expert Andre Goy, M.D., has to say about it.

The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.

Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.

Girls Gone Rx sponsors all-female fitness competitions to raise money for Bright Pink, a nonprofit that focuses on prevention and early detection of breast and ovarian cancer.

Mike Schmidt developed stage 3 melanoma after years of playing professional baseball for the Philadelphia Phillies.

One expert discusses current standard-of-care regimens as well as new combinations on the horizon for patients with myeloma who are not eligible to receive a stem cell transplant.

The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).

Ryan Mitstifer is not like most 15-year-old boys. This weekend, while others may have been found hanging out with friends or catching up on schoolwork, Ryan is out spreading the word about ovarian cancer.

CURE sat down with Richard Boulay, M.D., at the 2018 National Ovarian Cancer Coalition to discuss exciting updates in ovarian cancer, as well as what advice he would offer to patients and caregivers who may be feeling overwhelmed.

The combination use of Cyramza (ramucirumab) plus docetaxel showed improvements in objective response rate (ORR) and a positive trend in overall survival (OS) among patients with advanced bladder cancer, according to additional results from the phase 3 RANGE trial.

The Food and Drug Administration (FDA) approved a next-generation sequencing (NGS) companion diagnostic assay that can detect BRCA1/2 genetic mutations, as well as the percentage of genomic loss of heterozygosity (LOH) in patients with ovarian cancer.

In particular, patients whose tumors have certain genetic mutations may respond especially well to this combination approach.

There are a number of different treatment options for patients with relapsed myeloma, and it is important that patients and providers dicuss health history to determine which one is best.

For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses.

In this week's episode of CURE Talks Cancer, we spoke with Kimberly Alexander, who became an advocate for minority health after her husband was diagnosed with multiple myeloma.

After being diagnosed with a rare cancer, professional runner Gabriele Grunewald became inspired to start a nonprofit that raised awareness for other rare cancers and empowered those who have them.

Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).

Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.

The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.

A new drug combination bested current standard of care in a clinical trial.

While drug shortages are a pressing problem in the world of oncology, only a small percentage of patients are actually aware of the issue, according to a recent study.

PARP inhibitors are continuing to create buzz in the ovarian cancer space, both as single agents and in combinations that are currently being examined in clinical trials.

Cancer Care Planning and Communications (CCPC) Act would make survivorship care plans more accessible to patients who are insured by Medicare.

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.